Head-to-head evidence
HiCM-188 (allogeneic iPSC-cardiomyocytes) vs iPSC-CL
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Cardiac cell therapy · full Heart Failure pipeline
HiCM-188 (allogeneic iPSC-cardiomyocytes)
Developed by HELP Therapeutics
NCT03763136 · Phase 1/2 · completed
The trial randomized 20 participants to hPSC-CM therapy or a sham comparator consisting of coronary artery bypass surgery alone, with outcome assessors masked to treatment assignment. Its primary endpoints were clinical safety outcomes, but results are not posted and the small sample limits the strength of the evidence.
Next expected readout: November 2026 · NCT06340048 (registry estimate)
iPSC-CL
Developed by HeartWorks
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT05647213 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HiCM-188 (allogeneic iPSC-cardiomyocytes)'s landscape · iPSC-CL's landscape